-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, V0UCpQk1pBpT3tNJVEuqjfcwLrRriiOdlp/s0fw/40n+Vr70RfK9XTVKE/1jUbtk BwDnyb/AvQAf8q5Hoa/EEg== 0001157523-08-004695.txt : 20080530 0001157523-08-004695.hdr.sgml : 20080530 20080530172833 ACCESSION NUMBER: 0001157523-08-004695 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080523 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers FILED AS OF DATE: 20080530 DATE AS OF CHANGE: 20080530 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABIOMED INC CENTRAL INDEX KEY: 0000815094 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042743260 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-09585 FILM NUMBER: 08871747 BUSINESS ADDRESS: STREET 1: 22 CHERRY HILL DR CITY: DANVERS STATE: MA ZIP: 01923 BUSINESS PHONE: 9787775410 MAIL ADDRESS: STREET 1: 22 CHERRY HILL DRIVE CITY: DANVERS STATE: MA ZIP: 01923 8-K 1 a5698276.txt ABIOMED, INC. 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: May 23, 2008 - -------------------------------------------------------------------------------- (Date of earliest event reported) ABIOMED, Inc. - -------------------------------------------------------------------------------- (Exact name of registrant as specified in its charter) Delaware 04-2743260 (State or other Jurisdiction (IRS Employer of Incorporation) Identification Number) 0-20584 (Commission File Number) 22 Cherry Hill Drive Danvers, MA 01923 (Address of Principal Executive Offices, including Zip Code) (978) 646-1400 (Registrant's Telephone Number, including Area Code) Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: | | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) - -------------------------------------------------------------------------------- ================================================================================ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) On May 23, 2008, our compensation committee made its annual compensation determinations for our executive officers. The committee determined the bonuses for fiscal 2008 performance, the salaries for fiscal 2009 and made the annual equity grants to executive officers. The compensation decisions made with respect to our executive officers who were named executive officers in our most recent proxy statement were as follows:
Shares Restricted Fiscal Fiscal Underlying Restricted Stock 2008 2009 Stock Options Stock (Performance Executive Officer Bonus Salary (4 year vesting) (4 year vesting) vesting) --------------------------------- ---------- ---------- ----------------- ----------------- ---------------- Michael R. Minogue, $354,000 $371,700 43,333 43,333 43,334 Chairman, CEO and President Daniel J. Sutherby, Chief $75,000 $236,385 10,000 9,000 6,000 Financial Officer Andrew J. Greenfield, Vice $75,000 $194,555 9,000 10,000 11,000 President Healthcare Solutions
================================================================================ SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Abiomed, Inc. By: /s/ Daniel J. Sutherby ------------------------- Daniel J. Sutherby Chief Financial Officer Date: May 30, 2008 -----END PRIVACY-ENHANCED MESSAGE-----